Koen Hartemink

Prof. dr.

Universitair Medisch Centrum Utrecht

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Medical Imaging Medical Imaging professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Prof. dr. Koen Hartemink is a faculty member at Leids Universitair Medisch Centrum in the Netherlands. His research focuses on oncology, particularly in the areas of non-small cell lung cancer, circulating tumor DNA, and novel treatment strategies for advanced gastrointestinal stromal tumors. He has contributed to several recent studies aimed at improving diagnostic and treatment outcomes for patients with complex cancer conditions.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (8)

Elke Van Daele

Ghent University Hospital

BELGIUM

View details

Robert Rintoul

Professor of Thoracic Oncology

University of Cambridge

UNITED KINGDOM

View details

Neil Merrett

Professor

University of Western Sydney

AUSTRALIA

View details

Florit Marcuse

Maastricht University Medical Centre

NETHERLANDS

View details

Michel M. van den Heuvel

Radboud University Medical Center

NETHERLANDS

View details

Kim Monkhorst

The Netherlands Cancer Institute

NETHERLANDS

View details

Jerry Braun

Head of department Pulmonary Surgery

Amsterdam University Medical Centers

NETHERLANDS

View details

Egbert Smit

Leiden University Medical Center

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Koen Hartemink

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study

Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial

The DETECTION project part 1: An international Delphi survey about diagnostics and treatment of anterior mediastinal cystic lesions

Survival difference between patients with single versus multiple metastatic lymph nodes and the role of histology in pathological stage II-N1 non-small cell lung cancer

The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy – a nationwide cohort study

Erratum to "Practice variation in anastomotic leak after esophagectomy: Unravelling differences in failure to rescue" [Eur J Surg Oncol 49 (5) (May 2023) 974-982].

Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GISTs) is Effective and Safe: Results from a Prospective Single-Center Study with 108 Patients.

Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens

Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients.

Reply to Peng et al.

Collaborators (8)

Elke Van Daele

Robert Rintoul

Neil Merrett

Florit Marcuse

Michel M. van den Heuvel

Kim Monkhorst

Jerry Braun

Egbert Smit

Make your next move.